IDeYA darovasertib NDA near completion; pipeline expands via new collaborations
IDEAYA says its darovasertib final NDA submission is imminent after positive FDA feedback, with new data to be presented at ESMO. Pipeline expansion includes a phase III DLL3 ADC trial and new Roche, PRMT5 and CDKN2A collaborations.
Final NDA submission for darovasertib is imminent, following positive FDA feedback, and new data is set to be presented at ESMO. The pipeline advances also include a phase III DLL3 ADC trial in small cell lung cancer, strategic collaborations with Roche, and expansion into PRMT5 and CDKN2A programs.